Bromodomain proteins are epigenetic readers. They do not chemically modify chromatin themselves; instead, they recognize acetylated lysine residues on histone tails and on certain non-histone proteins, and recruit transcriptional regulators and chromatin-remodeling complexes to those acetylated regions. The human genome encodes 61 bromodomains distributed across 46 proteins, organized into eight major evolutionary families. All bromodomains share a conserved four-helix fold, with the ZA and BC loops forming a hydrophobic pocket that binds acetyl-lysine through a conserved asparagine residue. Variation in these loops determines which acetylation patterns each bromodomain recognizes, and this structural diversity underlies the remarkable functional specialization within the family, from transcriptional activation and enhancer regulation to DNA repair and innate immune signaling.

The most intensively studied bromodomain proteins in virology belong to the bromodomain and extra-terminal (BET) family: BRD2, BRD3, BRD4, and BRDT. These proteins carry two tandem bromodomains and an extra-terminal domain, and BRD4 and BRDT additionally possess a C-terminal domain that interacts with positive transcription elongation factor b (P-TEFb), a complex of CDK9 and Cyclin T1 that drives RNA polymerase II-dependent transcriptional elongation. Because integrated retroviruses depend entirely on host transcription machinery, BET proteins sit at the heart of how HIV-1 and HTLV-1 control expression of their genomes. Non-BET bromodomain proteins, by contrast, often operate within ATP-dependent SWI/SNF chromatin-remodeling complexes, where they regulate chromatin accessibility rather than elongation directly.

In HIV-1 infection, the role of BRD4 has been defined over two decades of work. Early studies identified BRD4 as a recruiter of P-TEFb to cellular promoters, and subsequent research revealed a more nuanced picture: BRD4 can act as a negative regulator of HIV transcription by competing with the viral Tat protein for access to P-TEFb. A conserved P-TEFb-binding domain within BRD4 inhibits HIV transcription, and related work showed that BRD4 modulates Tat-dependent elongation through phosphorylation of CDK9 at threonine 29. Later studies demonstrated that BRD4 liberates P-TEFb from the inhibitory 7SK snRNP complex through a dual-binding mechanism, and that BRD4 is also an atypical kinase capable of phosphorylating serine 2 of the RNA polymerase II C-terminal domain. Together these findings established the Tat–P-TEFb axis, and BRD4’s position within it, as a central determinant of HIV-1 gene expression.

Bromodomain proteins also govern HIV latency, the state in which proviral DNA sits transcriptionally silent in host chromatin, forming the reservoir that prevents eradication of the virus. BET inhibition with compounds such as JQ1 reactivates latent HIV-1, both by antagonizing BRD4-mediated repression of Tat transactivation and through Tat-independent mechanisms. Notably, the short isoform of BRD4 was shown to promote latency by recruiting repressive SWI/SNF complexes to the proviral promoter, a finding that directly connected bromodomain biology to chromatin-remodeling machinery. Genome-wide CRISPR screens have since confirmed that latency is maintained by interconnected epigenetic and transcriptional pathways rather than by any single host factor. Therapeutically, BET inhibitors have been explored both as latency-reversing agents for shock-and-kill strategies and, in the case of BRD4-selective molecules such as ZL0580, as block-and-lock compounds that durably suppress proviral transcription.

Against this backdrop, BRD9 has recently entered the field. BRD9 is not a BET protein; it contains a single bromodomain with a distinctive tyrosine gatekeeper residue and serves as a defining component of the non-canonical BAF (ncBAF) complex, one of three compositionally distinct mammalian SWI/SNF assemblies alongside canonical BAF and PBAF. ncBAF contains BRD9 together with GLTSCR1 or GLTSCR1L, and its ATP-dependent remodeling activity alters nucleosome positioning and the accessibility of regulatory DNA. In 2025, Luk and colleagues provided the first direct experimental evidence that BRD9-containing ncBAF complexes regulate chromatin accessibility at the HIV-1 provirus, influencing proviral transcriptional competence, latency maintenance, and viral reactivation. Using complementary genetic and pharmacological approaches, the study established BRD9 as a bona fide host factor involved in HIV persistence, and suggested that selective BRD9 inhibition could support block-and-lock strategies aimed at durable proviral silencing.

The review’s authors are careful to stress that this single study marks the beginning, not the culmination, of BRD9 research in retrovirology. Independent validation, mechanistic work across multiple reservoir cell types, and characterization of BRD9 interaction partners remain necessary. Several fundamental questions are unresolved: how BRD9 is recruited to retroviral chromatin, whether it cooperates with or acts independently of BRD4, and what its genomic occupancy at proviral loci looks like. The authors also caution that most bromodomain-targeted compounds evaluated in HIV cure research, including JQ1, CPI-203, and OTX015, are pan-BET inhibitors, so their antiviral effects cannot be attributed to BRD9. Future studies will require selective BRD9 inhibitors or degraders to distinguish BRD9-specific mechanisms from the broader consequences of BET inhibition.

The picture for HTLV-1 is even more preliminary. No direct experimental study has yet examined BRD9 in HTLV-1 infection. What is established comes almost entirely from BET protein research. The viral transactivator Tax was shown to modulate the BRD4–P-TEFb interaction, competing with BRD4 and with the inhibitory 7SK snRNP/HEXIM1 complex to increase the pool of active P-TEFb available for the HTLV-1 long terminal repeat promoter. BET inhibition with JQ1 suppresses Tax-mediated cellular transformation and reduces NF-κB signaling, a pathway constitutively activated in HTLV-1-transformed cells. More recently, BET inhibition disrupted the BATF3/IRF4-dependent transcriptional network essential for adult T-cell leukemia/lymphoma (ATLL) cell survival, supporting the idea that ATLL cells are transcriptionally addicted to bromodomain-regulated programs. Resistance, however, is a documented challenge: loss of FBXW7-mediated BRAF degradation promotes BET inhibitor resistance in ATLL cells through sustained MAPK signaling, underscoring the likely need for combination therapies.

Whether BRD9 contributes to HTLV-1 transcription, proviral chromatin organization, Tax- or HBZ-mediated regulation, or ATLL leukemogenesis remains entirely unknown, and the review presents it only as a biologically plausible, untested candidate. Given ncBAF’s roles in enhancer accessibility, three-dimensional chromatin architecture, and signaling-dependent transcription, the question is well worth asking. The authors propose a research agenda: mapping BRD9 genomic occupancy with ChIP-seq, CUT&RUN, CUT&Tag, and single-cell multi-omics; identifying viral and cellular interaction partners proteomically; testing BRD9 function across HIV reservoirs including resting CD4-positive T cells, macrophages, and tissue-resident immune cells; and evaluating selective BRD9 inhibitors, degraders, and PROTACs in preclinical retroviral models. If BRD9-specific modulation proves feasible and safe, it could open a genuinely new epigenetic front in the effort to control retroviral persistence, reverse latency, or prevent retrovirus-associated malignancy, while reinforcing a broader lesson of the field: bromodomain proteins are not a single mechanistic class, but a diverse family of chromatin readers whose individual contributions to viral pathogenesis must each be established on their own experimental footing.

Subject of Research: The roles of bromodomain-containing proteins, particularly BRD9 and BRD4, in regulating chromatin, transcription, and latency during HIV-1 and HTLV-1 infection

Article Title: BRD proteins in human retroviral infection: emerging evidence from HIV-1 and future perspectives for HTLV-1

Article References: Akbarin, M. M., Farjami, Z., & Álvarez, H. R. (2026). BRD proteins in human retroviral infection: emerging evidence from HIV-1 and future perspectives for HTLV-1. Molecular Biology Reports, 53(1), Article 1603. https://doi.org/10.1007/s11033-026-12778-8

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12778-8

Keywords: BRD9, BRD4, bromodomain proteins, HIV-1, HTLV-1, viral latency, chromatin remodeling, ncBAF, P-TEFb, epigenetics, ATLL, retrovirus

Thymidine kinase has long occupied a central place in herpesvirus research. The enzyme phosphorylates thymidine and related nucleosides, feeding nucleoside monophosphates into the viral DNA replication pathway. In non-dividing cells such as neurons, where the host cell’s own nucleotide pools and salvage pathways are limited, viral thymidine kinase becomes essential for efficient genome synthesis. It is also a key determinant of reactivation from latency, the process by which a dormant neuronal infection resumes productive replication and spreads to new hosts. Antiviral drugs such as acyclovir exploit the enzyme’s substrate specificity, because the kinase phosphorylates these drugs into toxic chain terminators preferentially in infected cells. Despite this importance, the mechanisms that govern where thymidine kinase accumulates inside an infected cell and how its activity is tuned during different phases of infection have remained poorly defined.

The new work began with the observation that thymidine kinase undergoes SUMOylation during authentic viral infection. SUMOylation is the covalent attachment of small ubiquitin-like modifier peptides to lysine residues of target proteins, a modification widespread in eukaryotic cells that typically alters protein interactions, stability, or localization without marking proteins for destruction the way ubiquitination often does. Viruses frequently co-opt or manipulate host SUMO machinery, and several viral proteins are themselves SUMOylated. The researchers showed that the pseudorabies virus thymidine kinase is conjugated not by a single SUMO paralog but by all three major forms found in mammalian cells, SUMO-1, SUMO-2, and SUMO-3, indicating that the modification is a genuine and broad feature of the protein’s life during infection rather than a rare or paralog-specific event.

Mapping the modification sites was the next step. Through mutational analysis, the team identified two lysine residues, K242 and K267, as the principal SUMO acceptor sites on the enzyme. These residues sit outside the catalytic core of the kinase, and when the investigators substituted them to prevent SUMO conjugation, they made a striking discovery: the mutant enzyme was neither destabilized nor catalytically impaired. Its stability inside infected cells was unchanged, and its kinase activity in vitro was preserved. What changed instead was where the protein went. Disruption of the SUMOylation sites markedly reduced the nuclear accumulation of thymidine kinase, shifting its distribution within the cell. In other words, SUMOylation functions not as an on-off switch for enzymatic activity but as a trafficking signal, ensuring that a fully competent enzyme reaches the compartment where it is needed.

The functional consequences of that mislocalization proved to be highly cell-type dependent. In dividing epithelial PK15 cells, a standard laboratory model for pseudorabies virus propagation, viruses carrying SUMOylation-deficient thymidine kinase replicated essentially normally. The modification was dispensable in this setting, presumably because epithelial cells provide abundant nucleotide pools and a permissive environment in which the cytoplasmic or diffuse distribution of the kinase suffices to support DNA synthesis. In neuronal N2a cells, however, the picture was entirely different. The SUMOylation-deficient virus replicated inefficiently in these non-dividing neuronal cells, demonstrating that nuclear delivery of thymidine kinase is a specific requirement for viral genome synthesis in the very cell type where the virus establishes its lifelong reservoir.

To connect this replication defect to the clinically and economically critical process of reactivation, the researchers employed an in vitro latency and reactivation model. They found that the SUMOylation-deficient virus was fully capable of establishing latent infection; the modification is not required for the virus to enter and persist in its dormant state. But when conditions were shifted to trigger reactivation, the mutant virus was markedly impaired, failing to resume productive replication efficiently. This dissociation between establishment and reactivation mirrors the known biology of thymidine kinase itself, which is dispensable for latency but essential for the resumption of lytic replication, and it places SUMOylation squarely within that reactivation pathway. The modification, in effect, arms the virus for exit from dormancy by ensuring the kinase is positioned correctly the moment replication restarts.

The in vivo significance of these findings was confirmed in a mouse infection model. Mice infected with the SUMOylation-deficient mutant virus experienced markedly attenuated disease compared with animals infected with wild-type pseudorabies virus. Viral loads in the brain were reduced, and histopathological lesions were milder, indicating that the loss of a single post-translational modification on one viral enzyme translates into a measurable loss of neuroinvasiveness and pathogenicity. Because pseudorabies virus is a close relative of the human alphaherpesviruses, including herpes simplex virus and varicella-zoster virus, the study raises the possibility that analogous SUMOylation events regulate thymidine kinase function in medically important human pathogens, although this remains to be tested directly.

Technically, the study illustrates the power of combining site-directed mutagenesis with cell-type-specific infection assays to dissect post-translational regulation. By separating effects on protein stability, catalytic activity, and subcellular localization, the authors were able to attribute the attenuation phenotype specifically to mislocalization rather than to a general loss of enzyme function. This distinction matters for antiviral strategy: a drug or therapeutic approach that blocks TK SUMOylation would not need to inhibit the kinase’s active site, which is shared in principle with cellular enzymes, but could instead prevent the enzyme from reaching its nuclear destination in neurons, selectively crippling the virus at the stage of neuronal replication and reactivation while sparing its replication in peripheral tissues.

The broader implication is that alphaherpesviruses encode their own localization control for a pivotal metabolic enzyme, and that this control is tuned to the biology of latency. A virus that must remain quiet for the lifetime of its host, yet be ready to reactivate at a moment’s notice, benefits from storing a fully active, correctly positioned replication factor in neurons. SUMOylation of thymidine kinase at K242 and K267 appears to provide exactly that readiness. As the authors conclude, the modification facilitates efficient neuronal replication, viral reactivation, and pathogenesis, and its disruption attenuates the virus without abolishing its ability to establish latency, a profile that could inform both vaccine design and the development of reactivation-blocking therapeutics. For a pathogen responsible for substantial losses in swine production worldwide, a single pair of lysine residues may prove to be an unexpectedly consequential target.

Subject of Research: SUMOylation-dependent nuclear localization of pseudorabies virus thymidine kinase and its role in neuronal replication and reactivation

Article Title: SUMOylation of pseudorabies virus thymidine kinase regulates its nuclear localization and facilitates neuronal replication and reactivation

Article References: Chen, X., Li, C., Xing, D., Song, J., Liu, Y., Liu, Y., Huang, Q., Kuang, Y., Li, X., Zhang, J., Zhang, Y., Zhang, N., Bai, R., Cheng, C., Yuan, J., Tang, J., & Zhang, R. (2026). SUMOylation of pseudorabies virus thymidine kinase regulates its nuclear localization and facilitates neuronal replication and reactivation. PLOS Pathogens, 22(10), e1014653. https://doi.org/10.1371/journal.ppat.1014653

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014653

Keywords: pseudorabies virus, alphaherpesvirus, thymidine kinase, SUMOylation, post-translational modification, nuclear localization, neuronal replication, viral reactivation, latency, UL23, PLOS Pathogens, antiviral targets

Antiretroviral therapy transformed HIV from a nearly uniform death sentence into a manageable chronic condition by blocking new rounds of infection. Yet the therapy does nothing to the proviral DNA already stitched into the genomes of long-lived host cells. As soon as treatment lapses, the reservoir seeds rapid viral rebound. Understanding why particular infected clones persist for years, while others decay, has therefore become one of the most consequential questions in HIV research, and the new findings suggest the answer lies partly in the immune environment the reservoir cells inhabit rather than in the virus alone.

Natural killer cells are innate lymphocytes that patrol the body and kill stressed or infected cells without requiring the antigen-specific recognition that defines T and B lymphocytes. Their activity is governed by a delicate balance of activating and inhibitory receptors. KIR2DL1 is an inhibitory killer-cell immunoglobulin-like receptor that recognizes specific HLA class I molecules, the same surface proteins that HIV-exposed cells display. The education model of NK cell biology holds that a developing NK cell calibrates its functional competence through interactions between its inhibitory receptors and self-HLA; a KIR2DL1-positive NK cell in an individual carrying the corresponding HLA ligand becomes ‘educated,’ or licensed, to respond vigorously when that ligand is lost or altered, as frequently happens during viral infection.

The study demonstrates that these education states are not a fleeting influence but leave durable imprints on the reservoir. By examining cells from people who had spent years, in some cases many years, on suppressive antiretroviral regimens, the researchers found that proviruses surviving over the long term were not distributed randomly across the infected cell population. Instead, their persistence correlated with features of the innate immune landscape, indicating that some infected cells had been preferentially spared or eliminated depending on how the NK cell compartment of that individual had been trained.

This reframes the reservoir as an active participant in a prolonged evolutionary standoff with the immune system. Cells harboring intact, replication-competent proviruses that somehow avoid NK-mediated killing gain a survival advantage and expand, sometimes through clonal proliferation, over years of therapy. Cells that present vulnerabilities to educated NK cells are progressively culled. The result is a reservoir sculpted by immune pressure, analogous in some respects to how antigen escape shapes the evolution of the virus in untreated infection, but operating here through germline-encoded innate receptors rather than clonal adaptive recognition.

The technical achievement underlying these conclusions is considerable. Single-cell approaches now allow researchers to connect proviral sequence, integration site, transcriptional state, and surface phenotype in the same individual cell, converting what was once a population-level average into a high-resolution map of reservoir heterogeneity. Combined with deep characterization of NK cell receptor repertoires and their HLA ligands in each study participant, such methods make it possible to ask which immune configurations leave measurable signatures on which reservoir lineages, and the study deployed precisely this integrative strategy across cohorts on long-term therapy.

The clinical implications are potentially far-reaching. Current cure strategies aim to ‘shock and kill’ the reservoir, using latency-reversing agents to force latent proviruses into expression so that immune or pharmacological effectors can destroy the exposed cells. If KIR2DL1-educated NK cells already exert selection pressure on the reservoir, then the efficiency of such interventions may depend heavily on whether the killing arm of the strategy is matched to the individual’s NK cell education status and HLA type. A shock-and-kill regimen delivered to a person whose NK cells are poorly licensed against their own reservoir cells might flush virus into the open without achieving meaningful depletion.

This line of thinking points toward precision immunotherapies for HIV. Just as cancer immunotherapy increasingly considers the tumor microenvironment and the patient’s innate immune competence, curative interventions for HIV may need to account for innate immune imprints. Engaging NK cells deliberately, through bispecific killer-cell engagers, cytokine modulation, or engineered NK products, could in principle tip the standoff in favor of the host. Conversely, therapies that inadvertently impair NK education or function might relax selection pressure and allow reservoir clones to expand unchecked during what was assumed to be stable suppression.

The findings also resonate with a broader shift in virology: the recognition that innate immunity is not merely a rapid first response but a long-lived determinant of infection outcomes. Trained immunity, NK cell memory-like behavior, and receptor education all illustrate that innate cells carry histories. In chronic infections treated for years with suppressive drugs, those histories accumulate and leave fingerprints on the surviving pathogen population. HIV, the most intensively studied persistent human virus, now appears to bear such fingerprints in its reservoir.

Substantial questions remain. The relationship between KIR2DL1 education and reservoir persistence will need to be validated across larger and more diverse cohorts, since KIR and HLA genotype distributions vary substantially across populations, and HIV epidemiology is concentrated in regions where such genetic diversity is greatest. Whether innate selection can be therapeutically harnessed to shrink the reservoir, or only to shape it, is unresolved. But the conceptual contribution is clear: the latent HIV reservoir is not hidden from the immune system in any absolute sense. It has been living under innate immune surveillance all along, and the cells that persist during long-term antiretroviral therapy are, in part, the survivors of that surveillance. Any credible path to a cure will have to reckon with the imprints that this ancient arm of immunity has already left on the virus’s last refuge.

Subject of Research: The influence of KIR2DL1-educated natural killer cells on the persistence of latent HIV-1 reservoir cells during long-term antiretroviral therapy.

Article Title: Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy

Article References: Tan, T. S., Sun, W., Gao, C., Viard, M., Walters, L. C., Lancien, M., Yuki, Y., Van, T. N., Casquero, C., Guo, X., Hoh, R., Haas, D. W., Michael, N., Kirk, G. D., Yendewa, G., Gandhi, R. T., Kassaye, S. G., Tien, P. C., Walker, B. D., … Lichterfeld, M. (2026). Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy. Nature Immunology. https://doi.org/10.1038/s41590-026-02637-w

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02637-w

Keywords: HIV-1, viral reservoir, natural killer cells, KIR2DL1, NK cell education, antiretroviral therapy, viral latency, innate immunity, HIV cure research, Nature Immunology, immunotherapy, proviral persistence